PCIA
REGN icon

Prime Capital Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Prime Capital Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
16,572
+2,656
+19% +$1.81M 0.1% 151
2026
Q1 		$10.8M Buy
13,916
+1,133
+9% +$867K 0.12% 136
2025
Q4 		$9.87M Buy
12,783
+309
+2% +$210K 0.12% 136
2025
Q3 		$7.01M Buy
12,474
+11,835
+1,852% +$6.69M 0.09% 156
2025
Q2 		$336K Sell
639
-456
-42% -$255K ﹤0.01% 734
2025
Q1 		$695K Buy
1,095
+596
+119% +$410K 0.01% 578
2024
Q4 		$355K Sell
499
-799
-62% -$671K 0.01% 664
2024
Q3 		$1.36M Buy
1,298
+19
+1% +$21.1K 0.02% 377
2024
Q2 		$1.34M Sell
1,279
-181
-12% -$175K 0.02% 380
2024
Q1 		$1.41M Buy
1,460
+609
+72% +$579K 0.02% 404
2023
Q4 		$747K Buy
851
+223
+36% +$184K 0.01% 483
2023
Q3 		$517K Buy
628
+98
+18% +$77K 0.01% 466
2023
Q2 		$381K Buy
+530
New +$409K 0.01% 537
2021
Q2 		– Sell
-5
Closed -$2K – 505
2021
Q1 		$2K Buy
+5
New +$2.43K ﹤0.01% 448

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prime Capital Investment Advisors's REGN Position: Q2 2026 in Review

Prime Capital Investment Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2026, buying an estimated $1.81M and bringing the position to 16,572 shares worth $10.3M. The position accounts for 0.1% of the portfolio, ranked #151.

Prime Capital Investment Advisors first reported a position in REGN in Q1 2021 and has held it in 14 quarters since. The position peaked at $10.8M in Q1 2026. 955 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Prime Capital Investment Advisors held 16,572 shares of Regeneron Pharmaceuticals worth $10.3M as of Q2 2026.
  • Prime Capital Investment Advisors bought 2,656 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.81M.
  • Regeneron Pharmaceuticals made up 0.1% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #151 holding.
  • Prime Capital Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • Prime Capital Investment Advisors's Regeneron Pharmaceuticals position peaked at $10.8M in Q1 2026.
  • 955 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.